SCHEMBL6935562

SCHEMBL6935562

Nc1cc(S(=O)(=O)O)cc(Cl)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP6 P55212 3/20 0.53
GAA P10253 3/20 0.53
NSD2 O96028 2/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
PLCG1 P19174 1/20 0.53
DNMT1 P26358 1/20 0.53
ALDH1A1 P00352 5/20 0.52
HSD17B10 Q99714 4/20 0.52
NT5E P21589 3/20 0.52
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ING2 Q9H160 1/20 0.45
THRB P10828 2/20 0.43
CA1 P00915 4/20 0.42
CA2 P00918 4/20 0.42
CA9 Q16790 3/20 0.42
TSHR P16473 3/20 0.42
CA12 O43570 2/20 0.42
CYP3A4 P08684 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3857115 0.87 ING2 (0.52) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL2811005 0.85 GAA (0.50) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL28022985 0.85 ING2 (0.50) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL4649751 0.84 CASP6 (0.62) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL9463563 0.83 CA1 (0.63) GAAL3MBTL1CYP2C9CYP2C19THRB
SCHEMBL29918476 0.83 NT5E (0.47) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL9297596 0.82 NT5E (0.46) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL9070253 0.80 ALDH1A1 (0.52) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL2865112 0.80 CA1 (0.64) CASP6GAANSD2L3MBTL1PLCG1
SCHEMBL176914 0.80 CASR (0.45) CASP6GAANSD2L3MBTL1PLCG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE49569-E1 Alkylamine derivative EA PHARMA CO., LTD. (JP) 2023-07-04 US disclosed
EP-2546231-B1 ALKYLAMINE DERIVATIVE EA PHARMA CO LTD (JP) 2018-11-07 EP disclosed
US-9561216-B2 Alkylamine derivative EA PHARMA CO., LTD. (JP) 2017-02-07 US disclosed
US-20160101091-A1 ALKYLAMINE DERIVATIVE AJINOMOTO CO., INC. (JP) 2016-04-14 US disclosed
US-9253997-B2 Alkylamine derivative AJINOMOTO CO., INC. (JP) 2016-02-09 US disclosed
US-9150505-B2 Prophylactic or therapeutic agent for diabetes or obesity AJINOMOTO CO., INC. (JP) 2015-10-06 US disclosed
US-20130237702-A1 ALKYLAMINE DERIVATIVE AJINOMOTO CO., INC. (JP) 2013-09-12 US disclosed
US-20130072491-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY AJINOMOTO CO., INC. (JP) 2013-03-21 US disclosed
EP-2546231-A1 ALKYLAMINE DERIVATIVE Ajinomoto Co., Inc. (JP) 2013-01-16 EP disclosed
EP-2543660-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY Ajinomoto Co., Inc. (JP) 2013-01-09 EP disclosed
US-4083839-A Unsymmetrical mono sulfo containing 1:2 azo, azo chromium complex dyes CIBA-GEIGY CORPORATION (US) 1978-04-11 US disclosed
US-RE29585-E DYEING WOOL CIBA-GEIGY CORPORATION (US) 1978-03-21 US disclosed
US-4067864-A FOR CELLULOSE OR POLYAMIDES CIBA-GEIGY AG (CH) 1978-01-10 US disclosed
US-4052386-A REACTIVE PHTHALOCYANINE DYESTUFFS CONTAINING A FLUOROPYRIMIDINYL GROUP BAYER AKTIENGESELLSCHAFT (DT) 1977-10-04 US disclosed
US-4039523-A YELLOW CIBA-GEIGY AG (CH) 1977-08-02 US disclosed
US-4033942-A Chromium complex dye, including azo and azo methine dye compounds CIBA-GEIGY AG (CH) 1977-07-05 US disclosed
US-4017477-A 3-Halogeno-6-hydroxy-pyridone-(2) azo dyestuffs CIBA-GEIGY AG (CH) 1977-04-12 US disclosed
US-4007164-A FIBER-REACTIVE, CELLULOSE, WOOL BAYER AKTIENGESELLSCHAFT (DT) 1977-02-08 US disclosed
US-3971738-A Heavy metal complexes of azo compounds containing a halogeno-2,3-dihydroxy pyridine coupling component CIBA-GEIGY AG (CH) 1976-07-27 US disclosed
US-3933785-A Azo compounds CIBA-GEIGY AG (CH) 1976-01-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072491-A1 PROPHYLACTIC OR THERAPEUTIC AGENT FOR DIABETES OR OBESITY CASR, GPR119, GLP1R CASP6 1826/4885GAA 475/4885NSD2 3648/4885
US-20160101091-A1 ALKYLAMINE DERIVATIVE CASR, TAAR5, TAAR1 CASP6 1829/4885GAA 3022/4885NSD2 1189/4885
US-20130237702-A1 ALKYLAMINE DERIVATIVE CASR, TAAR5, TAAR1 CASP6 1829/4885GAA 3022/4885NSD2 1189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.